apollo

Select Address

Search Medicines
  • Login
  1. Home
  2. Nuclastaml Injection 1 ml

  3. Nuclastaml Injection 1 ml Substitute

Nuclastaml Injection 1 ml Substitute

Substitutes safety advice
call Doctor

Verified Ingredients and Effects

Composition:

DENOSUMAB-60MG

Uses:

Nuclastaml Injection 1 ml used to treat osteoporosis, bone loss, giant cell tumour of the bone, and high calcium levels. The detailed uses of Nuclastaml Injection 1 ml are as follows: <br/>• Management of Osteoporosis: Nuclastaml Injection 1 ml treats osteoporosis in postmenopausal women, increasing bone density and reducing fracture risk.<br/>• Giant cell tumour of the bone treatment: Nuclastaml Injection 1 ml is prescribed for the treatment of giant cell tumour of the bone, which helps by reducing tumour size and slowing its growth.<br/>• Increases bone mass: Nuclastaml Injection 1 ml increases bone mass in patients at high risk for fracture, including those undergoing androgen deprivation therapy for prostate cancer or adjuvant aromatase inhibitor therapy for breast cancer.<br/>• Hypercalcemia Treatment: Nuclastaml Injection 1 ml treats hypercalcemia caused by cancer, helping normalise calcium levels in the blood.<br/>• Paget's Disease: Nuclastaml Injection 1 ml treats Paget's disease by alleviating bone pain and complications caused by enlarged and deformed bones.<br/>

Medicinal Benefits:

Nuclastaml Injection 1 ml belongs to a group of medicines called RANK ligand inhibitors used to treat osteoporosis in postmenopausal women and men who have an increased risk of fracture. Nuclastaml Injection 1 ml is also used to treat bone loss due to reduced hormone levels caused by surgery or due to treatment with medicines in patients with prostate cancer. It is also used to treat bone loss occurring due to long-term treatment with glucocorticoids in patients who are at an increased risk of fractures. Nuclastaml Injection 1 ml may also be used to reduce the risk of fractures in people with multiple myeloma, giant cell tumours of the bone and to treat high calcium levels caused by cancer. Nuclastaml Injection 1 ml binds to a protein on RANK ligand on osteoclast (cells that cause bone breakdown) and inhibits their formation, functioning and survival. It decreases bone breakdown, increases bone density, and strengthens the bone. Nuclastaml Injection 1 ml treats giant cell tumour of bone (GCTB) by blocking certain receptors in the tumour cells, thereby slowing the growth of the tumour. Nuclastaml Injection 1 ml helps treat high calcium levels by decreasing bone breakdown, as the breakdown of the bones releases calcium. Nuclastaml Injection 1 ml makes the bones stronger and less likely to break.

FAQs

Nuclastaml Injection 1 ml is used to treat osteoporosis in postmenopausal women and men who have an increased risk of fracture. It is also used to treat bone loss and reduce the risk of fractures.

Nuclastaml Injection 1 ml binds to a protein on RANK ligand on osteoclast (cells that cause bone breakdown) and inhibits their formation, functioning and survival. Thereby decreases bone breakdown, increases bone density, and strengthens the bone. Nuclastaml Injection 1 ml makes the bones stronger and less likely to break.

Osteonecrosis of the jaw (bone damage in the jaw) might be a side-effect of Nuclastaml Injection 1 ml. The risk increases in people taking Nuclastaml Injection 1 ml for longer durations. It might also occur upon discontinuation of the treatment. Maintain good dental hygiene and receive regular dental check-ups whilst on treatment with Nuclastaml Injection 1 ml. Inform your doctor if you have dental problems, gum disease, planned tooth extractions, cancer, if you smoke, or are taking bisphosphonates or corticosteroids.

Breakdown of bones releases calcium and causes hypercalcemia (high calcium levels in the blood). Nuclastaml Injection 1 ml helps treat high calcium levels by decreasing bone breakdown.

Unusual thigh bone fractures might occur whilst on treatment with Nuclastaml Injection 1 ml. Consult your doctor if you experience new or unusual pain in the thigh, hip, or groin.

Nuclastaml Injection 1 ml treats giant cell tumour of bone (GCTB) by blocking certain receptors in the tumour cells, thereby slows the tumour growth. Giant cell tumour of the bone is a non-cancerous tumour that typically grows at the ends of long bones.

Nuclastaml Injection 1 ml might cause skin infections. Consult your doctor immediately if you notice symptoms such as swollen skin, redness, cellulitis (hot and tender skin), commonly in the lower leg with feverish symptoms.

Nuclastaml Injection 1 ml has been used safely for up to 8 years, showing substantial increases in bone density during that time. However, the optimal duration of therapy varies depending on individual health conditions and needs. Long-term use should be closely monitored by your healthcare provider to assess benefits, risks, and the need for continued therapy. Always consult the doctor for personalized guidance.

Some people may experience hair loss while using Nuclastaml Injection 1 ml. However, individual reactions to medications can vary. If you experience hair loss or any unusual symptoms while taking Nuclastaml Injection 1 ml, consult the doctor to determine the cause and discuss appropriate management options.

No, Nuclastaml Injection 1 ml is not a chemotherapy medication. It is a monoclonal antibody which is used to treat conditions like osteoporosis, and bone loss associated with certain cancers, and to prevent bone fractures in patients with metastatic bone disease. It targets a protein called RANKL to inhibit bone breakdown, thereby increasing bone strength and density.

Nuclastaml Injection 1 ml is administered subcutaneously (under the skin) in your upper arm, upper thigh, or stomach area by the doctor or nurse, usually given once every 6 months for osteoporosis. Your doctor will determine the exact schedule based on your condition. Always follow the doctor's instructions regarding dosage and scheduling, as it may vary based on your specific medical condition.

You should inform your doctor before receiving Nuclastaml Injection 1 ml, as it is not recommended during pregnancy due to the potential risk of harm to the foetus.

Nuclastaml Injection 1 ml should be stored in a refrigerator at a temperature between 2°C and 8°C. Do not freeze it. Keep the vial in its outer carton to protect it from light.

The side effects of Nuclastaml Injection 1 ml include abdominal discomfort, bone/joint/muscle pain, arm/leg pain, constipation, and painful/frequent urination. Consult the doctor if any of these side effects persist or worsen.